[PDF][PDF] Bortezomib plus dexamethasone induction improves outcome of patients with t (4; 14) myeloma but not outcome of patients with del (17p)
H Avet-Loiseau, X Leleu, M Roussel, P Moreau… - Journal of Clinical …, 2010 - bhs.be
H Avet-Loiseau, X Leleu, M Roussel, P Moreau, C Guerin-Charbonnel, D Caillot, G Marit…
Journal of Clinical Oncology, 2010•bhs.bePurpose Cytogenetics is an important prognostic parameter in multiple myeloma (MM).
Patients presenting with either t (4; 14) or del (17p) are known to have a short event-free
survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is
able to overcome these prognostic parameters.
Patients presenting with either t (4; 14) or del (17p) are known to have a short event-free
survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is
able to overcome these prognostic parameters.
Purpose
Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t (4; 14) or del (17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic parameters.
bhs.be